Cilostazol in the management of atherosclerosis

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 363-372

  Sallustio, Fabrizio ^a,b   Rotondo, Federica ^c   Legge, Silvia Di ^a,b   Stanzione, Paolo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiplatelet agents; Atherosclerosis; Cilostazol; Phosphodiesterase inhibitor; Vascular prevention

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTICOAGULANT AGENT; ATENOLOL; C REACTIVE PROTEIN; CASPASE; CILOSTAZOL; CLOPIDOGREL; CYCLIC AMP; DIPYRIDAMOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NIFEDIPINE; P21 ACTIVATED KINASE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROTEIN BAX; PROTEIN P53; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

APOPTOSIS; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CARDIOVASCULAR RISK; CAUSE OF DEATH; CELL ACTIVATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DEMENTIA; DIABETES MELLITUS; DIARRHEA; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVATION; FECES; FOLLOW UP; HEADACHE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PALPITATION; HEART PROTECTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INTERMITTENT CLAUDICATION; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; PULSE RATE; RESTENOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SMOOTH MUSCLE FIBER; SUBARACHNOID HEMORRHAGE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT CONTRAINDICATION; UPREGULATION; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; DISEASE MANAGEMENT; HUMANS; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; TETRAZOLES;

EID: 77952896985     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112331     Document Type: Article

References (124)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-9.
2. Murray CJL, Lopez LD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
4. The World Heath Report. Reducing risks, promoting healthy lives. Geneva (Switzerland); World Health Organization 2002.
5. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-206.
6. Sabouret P, Cacoub P, Dallongeville J, et al. REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year. Arch Cardiovasc Dis 2008; 101: 81-8.
7. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Part I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
8. Shafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
9. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
10. Yusuf S, Zhao F, Metha SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
11. Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
12. Bhatt DL, Fox KA, Hacke W, et al.; CHARISMA investigators. Clopidogrel and aspirin vs. aspirin alone for prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
13. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4: S14-9.
14. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl 2005; 6: 13-9.
15. Packer M. Cardiovascular and Renal Drugs Advisory Committee, 85th Meeting Bethesda, MD: Food and Drug Administration, U.S. Department of Health and Human Services, July 9, 1998.
16. Sorkin EM, Markham A. Cilostazol. Drugs Aging 1999; 14: 63-71
17. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 Inhibitor. Thromb Haemostas 1999; 2: 435-8.
18. Sun B, Le SN, Lin S, et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharm 2002; 40: 577-85.
19. Huttemann E, Ukena D, Lenschow V, Schwabe U. Adenosine receptors in human platelets: characterization by 5' -Nethylcarboxamido [3H] adenosine binding in relation to adenylate cyclase activity. Naunyn Schmiedebergs Arch Pharmacol 1984; 325: 226-33.
20. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al. Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 2001; 21: 178-82.
21. Dawicki DD, Agarwal KC, Parks RE Jr. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor. Thromb Res 1986; 43: 161-75.
22. Wesley MC, McGowan FX, Castro RA, Dissanayake S, Zurakowski D, Dinardo JA. The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg 2009; 108: 1425-9.
23. Barradas MA, Jagroop A, O'Donoghue S, Jeremy JY, Mikhailidis DP. Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study. Thromb Res 1993; 71: 227-36.
24. Goto S. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 149-56.
25. Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-47.
26. Goto S, Tamura N, Handa S, Arai M, Kodama K, Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002; 106: 266-72.
27. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001; 20: 2120-30.
28. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis Suppl 2006; 6: 3-11.
29. Strony J, Beaudoin A, Brands D, Adelman B. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol 1993; 265: 1787-96.
30. Ikeda Y, Handa M, Kawano T, et al. The role of von Willebrand factor and fibrinogenin platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
31. Nakamura T, Uchiyama S, Yamazaki M, Iwata M. Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation. Thromb Res 2007; 119: 511-6.
32. Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K. Inhibition of platelet aggregation and the release of Pselectin from platelets by cilostazol. Thromb Res 2001; 101: 445-53.
33. Ishikawa M, Cooper D, Russell J, et al. Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 2003; 34: 1777-82.
34. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atherosclerosis Suppl 2006; 6: 13-9.
35. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38: 710-3.
36. Hashimoto A, Miyakoda G, Yoshimi H, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006; 189: 350-7.
37. Omi H, Okayama N, Shimizu M, et al. Cilostazol inhibits high glucose-meediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 2004; 68: 119-25.
38. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000; 152: 299-305.
39. Lee JH, Oh GT, Park SY, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005; 313: 502-9.
40. Okutsu R, Yoshikawa T, Nagasawa M, et al. Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis 2009; 204: 405-11.
41. Kochanek PM, Hallenbeck JM. Polymorphonuclear leucocytes and monocyte/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-79.
42. Feuerstein GZ, Lui T, Barone FC. Cytokines, inflammation and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994; 6: 341-60.
43. Bredesen DE. Neural apoptosis. Ann Neurol 1995; 38: 839-51.
44. Chen J, Graham SH, Nakayama M, et al. Apoptosis repressor genes Bcl-2 and Bcl-x-long are expressed in the rat brain following global ischemia. J Cereb Blood Flow Metab 1997; 17: 2-10.
45. Jürgensmeier J, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome C from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95: 4997-5002.
46. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002; 300: 787-93.
47. Fisher M, Albers GW. Application of diffusion-perfusion magnetic resonance imaging in acute ischaemic stroke. Neurology 1999; 52: 1750-6.
48. Lee JH, Lee YK, Ishikawa M, et al. Cilostazol reduces brain lesion induced by focal cerebral ischaemia in rats: an MRI study. Brain Res 2003; 994: 91-8.
49. Honda F, Imai H, Ishikawa M, et al. Cilostazol attenuates gray and white matter damage in a rodent of focal cerebral ischemia. Stroke 2006; 37: 223-8.
50. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat. Brain Res 2007; 1152: 182-90.
51. Wakida K, Morimoto N, Shimazawa M, et al. Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and - 2. Brain Res 2006; 1116: 187-93.
52. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertnsion 1989; 13: 968-72.
53. Contard F, Sabri A, Glukhova M, et al. Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats. Hypertension 1993; 22: 665-76.
54. Pauletto P, Da Ros S, Caprini A, Chiavegato A, Pessina AC, Sartore S. Smooth muscle cell types at different aortic levels and in microvasculature of rabbits with renovascular hypertension. J Hypertens 1995; 13: 1679-85.
55. Kocher O, Gabbiani F, Gabbiani G, et al. Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening. Biochemical and morphologic studies. Lab Invest 1991; 65: 459-70.
56. Sjolund M, Madsen K, von der Mark K, Thyberg J. Phenotype modulation in primary cultures of smooth-muscle cells from rat aorta. Synthesis of collagen and elastin. Differentiation 1986; 32: 173-80.
57. Aikawa M, Sakomura Y, Ueda M, et al. Redifferentiation of smooth muscle cells after coronary angioplasty determined via myosin heavy chain expression. Circulation 2000; 96: 82-90.
58. Fujita Y, Lin J-X, Takahashi R, Tomimoto H. Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke prone spontaneously hypertensive rats. Brain Res 2008; 1203: 170-6.
59. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
60. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280: 1930-5.
61. Kubo M, Kiyohara Y, Kato I, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349-54.
62. Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke 2000; 31: 2616-22.
63. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005 15; 6: 33-40.
64. Yamada Y, Metoki N, Yoshida H, et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 2008; 39: 2210-8.
65. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia 2002; 45: 188-94.
66. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
67. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-7.
68. Touboul PJ, Elbaz A, Koller C, Lucas C, Adraï V, Chédru F for the GENIC Investigators. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. Circulation 2000; 102: 313-8.
69. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-22.
70. Sivenius J, Laakso M, Riekkinen Sr P, Smets P, Loewnthal A. European Stroke Prevention Study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. Stroke 1992; 23: 851-4.
71. Grotta JC, Norris JW, Kamm B and the TASS Baseline and Angiographic Data Subgroup. Prevention of stroke with ticlopidine: who benefits most? Neurology 1992; 42: 111-5.
72. Huang Y, Cheng Y, Wu J, Yansheng L, Xu E, Hong Z, for the cilostazol vs. aspirin for secondary ischaemic stroke prevention (CASISP) cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol 2008; 7: 494-9.
73. The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) study group-Aspirin plus dipyridamole vs. aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006; 367: 1665-73.
74. Hiatt WM, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: a study in long-term effects). J Vasc Surg 2008; 47: 330-6.
75. Stone WM, Demaerschalk BM, Fowl RJ, Money SR. Type 3 Phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. J Stroke Cerebrovasc Dis 2008; 17: 129-33.
76. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39.
77. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000; 86: 499-503.
78. Kwon SU, Cho Y-J, Koo J-S, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005; 36: 782-6.
79. Bauters C, Isner JM. The biology of restenosis. In: Topol EJ, Ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven 1998; pp. 2465-90.
80. John S, Douglas Jr. Role of adjunct pharmacologic therapy in the era of drug-eluting stents. Atheroscler Suppl 2006; 6: 47-52.
81. American Heart Association. Heart disease and stroke statistics2004 update. Dallas, Texas; 2003.
82. Casscells W, Engler D, Willerson JT. Mechanism of restenosis. Tex Heart Inst J 1994; 21: 68-77.
83. Miano JM, Vlastic N, Tota RR, Stemerman MB. Localization of FOS and JUN proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol 1993; 142: 715-24.
84. Riessen R, Wight TN, Pastore C, Henley C, Isner JM. Distribution of hyaluronian during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 1996; 93: 1141-7.
85. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Invest. N Engl J Med 1998; 339: 1665-71.
86. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
87. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation vs. antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126-32.
88. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation vs. antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation vs. aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98: 1597-603.
89. Foussas S, Alexopoulos D, Stefanadis C, et al. Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. Angiology 2000; 51: 289-94.
90. Ge J, Han Y, Jiang H, Sun B, Chen J, Zhang S. RACTS: A prospective Randomized Antiplatelet Trial of cilostazol vs. Ticlopidine in Patients Undergoing Coronary Stenting. J Cardiovasc Pharmacol 2005; 46: 162-6.
91. Schleinitz MD, Olkin I, Heidenreinch PA. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a metaanalysis of randomized trials. Am Heart J 2004; 148: 990-7.
92. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288: 2411-20.
93. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary interventions: The PCI-CURE study. Lancet 2001; 358: 527-33.
94. Morishita R. A scientific rationale for the CREST Trial results: Evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl 2005; 6: 41-6.
95. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-32.
96. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000; 86: 499-503.
97. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-32.
98. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
99. Serebruany VL, Steinhulb SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
100. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-9.
101. Gurbel PA, Blinden KP, Somara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 2005; 46: 1827-32.
102. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohera T, Imaizumi T. Platelet P-Selectin play an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005; 45: 1280-6.
103. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-Selectin on adherent platelets. Nature 1992; 359: 848-51.
104. Lee SW, Park SW, Hang MK, et al. Triple vs. dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-7.
105. Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007; 71: 1867-72.
106. Ahn Y, Jeong MH, Jeang JW, et al. Randomized comparison of cilostazol vs clopidogrel after Drug-Eluting stenting in Diabetic Patients - CIDES Trial Circ J 2008; 72: 35-9.
107. Lee S-W, Park S-W, Kim Y-H, Yun S-C, Park D-W, Lee C-W. Drug-Eluting stenting followed by cilostazol treatment Reduces Late Restenosis in Patients with Diabetes Mellitus. The DECLARE-DIABETES Trial. J Am Coll Cardiol 2008; 51: 1181-7.
108. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ. Mortality over a period of 10 years in patients with peripheral artery disease. N Engl J Med 1992; 326: 381-6.
109. Newman AB, Siscovick DS, Manolio TA, et al. for the Cardiovascular Health Study Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993; 88: 837-45.
110. Ridker PM, Cushman M, Stampfef MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-8.
111. Hoogeveen EK, Kostense PJ, Beks AJM, et al. Hyperhomocysteinemia is associated with an increase risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-8.
112. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. ß blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991; 3003: 1100-4.
113. Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
114. Food and Drug Administration. Internal analgesic, antipyretics, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antiacid drug products. Fed Reg 1998; 63: 56802-17.
115. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
116. The Hearth Outcomes Prevention Evaluation Study Investigators. Effects of the angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
117. Hearth Protection Study Collaborative Group. MRC/BHF Hearth Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
118. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
119. TASC working group. Management of peripheral arterial disease (PAD): TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; S1: 1-134.
120. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-30.
121. Hiatt WR. The US experience with cilostazol in treating intermittent claudication. Artheriosclerosis 2006; S6: 21-3.
122. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; 1: CD003748
123. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87S: 28D-33D.
124. ESPRIT Study Group. Aspirin plus dipyridamole vs. aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006; 367: 1665-73.